A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191 Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hay, Annette E
  • Murugesan, Alli
  • DiPasquale, Ashley M
  • Kouroukis, Tom
  • Sandhu, Irwindeep
  • Kukreti, Vishal
  • Bahlis, Nizar J
  • Lategan, Johan
  • Reece, Donna E
  • Lyons, John F
  • Sederias, Joana
  • Xu, Hao
  • Powers, Jean
  • Seymour, Lesley K
  • Reiman, Tony

publication date

  • June 2, 2016